Latest news with #LalPathLabs
Time of India
5 days ago
- Sport
- Time of India
Imane Khelif is man: Leaked Lal PathLabs' report unveils the dark reality of the Olympic gold medalist
A leaked medical report has reignited fierce debate over gender eligibility in elite sport after revealing that Algerian boxer Imane Khelif , the reigning Olympic champion, has male chromosomes. The test, conducted by India-based Dr Lal PathLabs in March 2023, stated plainly: 'Chromosome analysis reveals male karyotype.' Khelif was initially barred from the Women's World Boxing Championships that year based on these results. But in 2024, she returned to the ring at the Paris Olympics — and won gold. Lab at centre of controversy The chromosome test was commissioned by the International Boxing Association (IBA) and carried out at Dr Lal PathLabs, a widely respected diagnostic lab headquartered in New Delhi. It holds accreditation from the American College of Pathologists and certification from the International Organisation for Standardisation (ISO), adding credibility to the test results. Despite these credentials, Olympic officials dismissed the findings. IOC president Thomas Bach called them 'part of a Russian-led misinformation campaign,' citing broader concerns around the IBA's governance. IOC spokesperson Mark Adams also said at a press briefing in Paris that such test results were 'ad hoc' and 'not legitimate.' 'I feared for my life': Reactions from the ring During the Paris Olympics, Khelif's strength in the ring drew sharp attention. In her opening bout, she faced Italy's Angela Carini, a seasoned boxer who left the ring in tears. Live Events 'I feared for my life during that fight,' Carini later said. Her comments weren't isolated. Mexican boxer Brianda Tamara Cruz, who faced Khelif in 2022, said: 'I don't think I had ever felt like that in my 13 years as a boxer, nor in my sparring with men.' Khelif defeated Taiwan's Lin Yu-ting in the final with a performance many described as 'physically one-sided' and 'uncomfortable to watch.' Observers compared it to 'watching a man beat a woman in the ring,' intensifying public outrage and calls for policy reform. World Boxing Federation demands sex verification In response to the backlash, World Boxing has announced that Khelif must now undergo mandatory chromosome testing before she can compete in any further female events. The 26-year-old has not yet submitted proof of female chromosomes. World Boxing has since introduced a new rule requiring PCR-based genetic testing for all athletes over 18 competing in women's divisions. This measure was directly prompted by the fallout from the Khelif case. A lab with longstanding legacy Dr Lal PathLabs, now at the centre of this global storm, is no newcomer to critical medical testing. Founded in 1949 by Dr Major S.K. Lal, the lab began with basic pathology services and a blood bank. Over decades, it expanded nationally and gained international recognition. By 2015, the company had launched a successful IPO and now operates 280 labs across India, including a National Reference Laboratory in Delhi and regional centres in Kolkata, Mumbai, and Bangalore. The human cost of policy gaps Khelif, for her part, denies all claims that she is biologically male. 'I was raised as a girl and have always identified as female,' she said. Her identity, however, has become the focal point in a much larger and emotionally charged conversation: Who should be allowed to compete in women's sport? And on what basis? Latin American federations have since urged that women's boxing be limited to athletes assigned female at birth. They cite not only fairness but safety — a core concern for many in the sport. The IOC's decision to allow Khelif to compete, despite medical data suggesting otherwise, has drawn criticism for lacking transparency and consistency. While the committee insists there was 'no valid reason' to disqualify her, others argue that the data should have at least triggered an independent review. The episode lays bare a fundamental challenge: how to balance inclusion with fairness, safety, and trust in women's sport. For many athletes, this isn't theoretical. It's personal. Imane Khelif's case has become a flashpoint in the ongoing global debate over gender eligibility in sport . It has raised uncomfortable questions that governing bodies can no longer ignore.
Mint
5 days ago
- Business
- Mint
Stocks to trade today: Trade Brains Portal recommends two stocks for 3 June
Stock market today: Indian benchmark indices endured a highly volatile session on Monday, 2 June, but managed to pare early losses and close with modest declines, as late-session buying by bulls helped lift sentiment. The Nifty 50 ended down 0.14% at 24,716, recovering 189 points from the day's low. The Sensex also clawed back from early losses to finish 77 points, or 0.09%, lower at 81,373. Against this backdrop, Trade Brains Portal has picked two stocks—one from the healthcare sector and the other from the finance sector. Stocks to trade today, recommended by Trade Brains Portal for 3 June: Dr. Lal PathLabs Ltd Current price: ₹ 2,777 Target price: ₹3,380 in 16-24 months Stop-loss: ₹ ₹2,475 Why it's recommended: Founded in 1949, Dr. Lal PathLabs is one of India's leading diagnostic chains, offering a comprehensive range of pathology and radiology services. Its pan-India presence includes 12,365 pick-up points (PUPs), 6,607 patient service centers (PSCs), and 298 clinical laboratories as of FY25. The company serves patients and healthcare providers with over 3,100 pathology tests, 1,400+ radiology/cardiology tests, and 385 test panels, operating across more than 23 countries. Key operational strengths include: A logistics backbone supported by 280+ satellite labs and 36 NABL accreditations. Partnerships with 150+ hospitals/labs. A medical team of 250+ physicians and 1,800+ employees. Financial Highlights (FY25) Revenue: ₹2,461 crore, up 10.5% YoY Ebitda: ₹696 crore, up 14.2%, with 28.3% margin PAT: ₹492 crore, up 35.9%, with a 20% net margin The management is guiding for 11–12% revenue growth in FY26, driven by test portfolio expansion and rising patient volumes. Ebitda margins are expected to hover around 27%, as the company invests in growth regions (especially South and West India), digital infrastructure, and talent acquisition. Read this | Dr Lal PathLabs feels margin heat as it chases growth, long-term outlook remains strong Growth Strategy Continued focus on digital expansion, including an AI-based recommendation engine to improve patient experience. Increasing depth in high-growth segments such as genomics, autoimmune disorders, and reproductive diagnostics. Accelerated presence in Tier-3 and Tier-4 cities, particularly in North and East India; 18 new labs added in FY25. Ongoing integration of Suburban Diagnostics (acquired in 2021) to broaden reach and service offerings. Emphasis on volume-led growth by increasing both patient footfall and tests per patient. Actively exploring inorganic growth opportunities through M&A, leveraging its strong brand recall. Risk factors: The accuracy of diagnostic services is critical. Any lapses due to operational errors, poor maintenance, or mishandling could damage reputation and trust. The diagnostic space remains fragmented and highly competitive, with pricing pressure from numerous unorganized players offering similar services. Mahindra & Mahindra Financial Services Ltd Current price: ₹ 260 Target price: ₹ 310 in 16-24 months Stop-loss: ₹ 230 Why it's recommended: Established in 1991, Mahindra Finance is among India's leading non-banking financial companies (NBFCs), catering to a wide customer base across rural and semi-urban India. The company operates a robust pan-India network with over 1,365 branches across 27 states and 7 Union Territories, covering 516,000 villages and 8,000 towns, and serving 11 million customers through 6,000+ dealers and 10 OEM partnerships. Its diverse portfolio spans vehicle loans, SME financing, home finance, insurance broking, mutual funds, personal loans, and fixed deposits, with an AUM of $14.1 billion. Read this | Three multibagger penny stocks to watch out for in 2025 Financial Highlights (FY25) Total disbursements: ₹60,741 crore, up from ₹58,647 crore in FY24 Profit after tax: ₹2,261 crore, up 16% YoY Total income: ₹18,530 crore, up 16% YoY Loan book: ₹1,16,214 crore, up 17% YoY Interest income: ₹16,566 crore, up 15% YoY Interest expenses: ₹8,415 crore, up 21% YoY The company maintained healthy asset quality, supported by a tech-led approach to underwriting and collections. Credit cost stood at 1.3%, net interest margin at 6.5%, and gross stage 3 (GS3) assets at 3.7%. The company maintained healthy asset quality, supported by a tech-led approach to underwriting and collections. Credit cost stood at 1.3%, net interest margin at 6.5%, and gross stage 3 (GS3) assets at 3.7%. Growth Drivers Mahindra Finance has focused on targeting resilient borrowers, digitizing processes via third-party API integrations, and using data analytics to drive collection efficiencies. The company's SME segment saw a 48% jump in disbursements, accounting for 5% of the total. Among vehicles: Passenger cars rose 8%, making up 41% of disbursements Tractor loans grew 3%, contributing 10% Pre-owned and three-wheeler financing accounted for 16% and 4%, respectively Commercial vehicle financing remained stable at 21% Other segments (farm implements, gensets, personal/consumer loans) grew 21%, contributing 2% Mahindra Finance's diversified portfolio and strong brand in rural markets position it well to benefit from increased rural spending and the uptick in auto and SME financing. Risk factors: Credit risk remains a concern, particularly in rural markets, where loan delinquencies could lead to higher NPAs and impact profitability. The company's dependence on multiple funding sources exposes it to liquidity risks, especially during times of financial market stress. Continued performance depends on effective risk management, prudent capital allocation, and strong administrative controls. Market Recap: 2 June Indian benchmark indices ended a volatile session with minor losses on Monday. The Nifty 50 opened at 24,669.70, lower than Friday's close of 24,750.70, and slipped to an intraday low of 24,526.15 before recovering to close at 24,716.60, down 34.10 points or 0.14%. The index remained above its 50-, 100-, and 200-day EMAs, while breaking past the 20-day EMA. Its Relative Strength Index (RSI) stood at 54.70. The Sensex opened at 81,214.42, also below its previous close of 81,451.01, and dipped to a low of 80,654.26 before closing at 81,373.75, down 77.26 points or 0.09%. The Sensex also broke through its 20-day EMA and had an RSI reading of 54.69. Among sectoral indices, PSU banks led the gains on expectations of a possible rate cut at the upcoming RBI policy meeting. The Nifty PSU Bank index jumped 2.43% to 7,145.30, driven by strong moves in Indian Overseas Bank, which climbed 5.42% to ₹42, and Bank of Maharashtra, which rose 6.82% to ₹57.66. Realty stocks also saw strong buying, with the Nifty Realty index rising 2.18% to 970.05. Brigade Enterprises led the pack with a gain of 5.29%. On the other hand, technology stocks underperformed. The Nifty IT index fell 0.69% to 37,063, with names like Mphasis and Persistent Systems losing nearly 2% each. The Nifty Metal index also declined, slipping 0.48% to 9,148.95, after former US President Donald Trump announced plans to double steel import tariffs to 50%. JSW Steel and Lloyds Metals & Energy were among the notable losers, falling 1.25% and 2.76%, respectively. Also read | Amara Raja's March quarter margin is an irritant. More trouble ahead? Asian markets were largely in the red, mirroring the cautious sentiment. Hong Kong's Hang Seng index dropped 0.57% to 23,157.97, while China's Shenzhen Component lost 0.86% to close at 10,040.63. Japan's Nikkei 225 slid 1.3% to 37,470.67. Meanwhile, the Dow Jones in the US managed a modest gain of 0.13% to close at 42,270.07, even as tensions flared between the US and China. Beijing accused Washington of violating the Geneva tariff truce and threatened to raise retaliatory tariffs on US steel and aluminium imports to 50%. Trade Brains Portal is a stock analysis platform. Its trade name is Dailyraven Technologies Pvt. Ltd, and its Sebi-registered research analyst registration number is INH000015729. Investments in securities are subject to market risks. Read all the related documents carefully before investing. Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before making any investment decisions.
Sky News AU
6 days ago
- Sport
- Sky News AU
Olympic boxer Imane Khelif's leaked lab results offer new evidence about her biological sex
Newly leaked test results prove that Olympic boxer Imane Khelif does have male chromosomes — after the International Olympic Committee dismissed the claims as 'not legitimate' and let her compete in the Paris 2024 Games. Khelif – a 26-year-old who has long maintained she is female — was found to have male XY chromosomes in a 2023 test carried out by an accredited Indian doctor, newly obtained test results leaked by 3 Wire Sports show. 'Chromosome analysis reveals male karyotype,' read the test results — referring to male chromosomes – which left Khelif barred from the 2023 women's World Boxing Championship in India. The test was conducted before that tournament by Dr. Lal Path Labs, a New Delhi lab with accreditation from the American College of Pathologists and certification from International Organization for Standardization, documents show. But despite those bona fides, the IOC dismissed the test as 'not legitimate' and 'ad hoc,' according to the Telegraph, and allowed Khelif to compete in the women's division at the 2024 Paris Olympic. Leaders of the Olympic committee went a step further and even suggested that the test could be misinformation planted by Russia – where World Boxing is based – to prevent the dominant athlete from competing on the world stage. Khelif went on to win gold in Paris and left the sport mired in controversy, while competitors expressed fears about facing her in the ring. Italy's Angela Carini said she feared for her life during an Olympic bout against Khelif that lasted just 46 seconds. The year before Khelif's chromosomal test, Mexico's Brianda Tamara Cruz also said she had a similar experience. 'I don't think I had ever felt like that in my 13 years as a boxer, nor in my sparring with men,' she said of their fight. The leak of Khelif's 2023 test comes just days after controversy was renewed when World Boxing mandated that athletes 18 and older must undergo genetic testing – which consists of a cheek swab — if they want to compete in any women's events. Khelif has never provided any evidence beyond her word to prove she is a woman, but has vowed to compete in the upcoming games. Originally published as Olympic boxer Imane Khelif's leaked lab results offer new evidence about her biological sex
India Today
6 days ago
- Sport
- India Today
Leaks from Indian lab drop bombshell on Olympic boxer Imane Khelif's biological sex
Newly leaked documents from a reputed Indian lab have claimed that Algerian Olympic boxer Imane Khelif is biologically male. The test, conducted in 2023, reportedly showed that Khelif has XY chromosomes, which are typically associated with male biology, the New York Post reported. According to the report, documents were obtained from Dr. Lal Path Labs, a certified lab in New Delhi accredited by the American College of Pathologists and the International Organisation for Standardisation (ISO). A chromosome analysis concluded: "Chromosome analysis reveals male karyotype."advertisementThe Russian-backed boxing authorities suspended Khelif from the 2023 Women's Boxing World Championship in India based on these findings. However, She was permitted to participate in the 2024 Summer Olympics in Paris, where she won OFFICIALS DISMISS TEST RESULT At the Olympics, the officials dismissed the test, questioning its legitimacy. They stated that there is a possibility of Russian interference aimed at damaging Khelif's reputation and improving their own athletes' chances. The Olympic committee denied any biological concerns, saying there was no valid reason to prevent Khelif from competing in the women's boxer Angela Carini faced Khelif during the Paris Olympics in a match that ended in just 46 seconds. After the match, she said, "I feared for my life during that fight."Mexican boxer Brianda Tamara Cruz, who fought Khelif in 2022, echoed similar feelings. "I don't think I had ever felt like that in my 13 years as a boxer, nor in my sparring with men," she 26, has denied all claims that she is male, stating that she was raised as a girl and has always identified as female. Must Watch
New York Post
6 days ago
- Sport
- New York Post
Olympic boxer Imane Khelif's leaked lab results offer new evidence about her biological sex
Newly leaked test results suggest that Olympic boxer Imane Khelif is a biological male — more than a year after her towering appearance at the Paris 2024 Olympics sparked international backlash. Imane Khelif, 26, was found to have XY chromosomes, according to the leaked results of a 2023 test carried out by an accredited Indian doctor. The results of that test led the Russian-controlled boxing authority to expel Khelif from the 2023 women's boxing World Championship in India. Advertisement Khelif came under massive scrutiny during the 2024 Paris Olympics when the Olympic governing body allowed her to compete. 'Chromosome analysis reveals male karyotype,' read the document, referring to male chromosomes, according to the results published 3 Wire Sports. Advertisement The tests were conducted at Dr. Lal Path Labs, a New Delhi lab with accreditation from the American College of Pathologists, and certification from International Organization for Standardization, the Telegraph reported. Despite that accredited source, leaders at the Paris Olympics claimed the results 'not legitimate' when allowing Khelif to compete – suggesting that the Russians had planted misinformation about Khelif to get a leg up in the games. Khelif — who has long denied being male and insisted she was raised a girl — went on to win gold in Paris.
